BMEA: Biomea Price Chart

Biomea Fusion, Inc. (BMEA) seeks global dominance in the therapy of metabolic disorders through the development of its inhibitor platform, yet the absence of profitable assets and Phase II clinical trials create a negative cash flow supported by investments at the level of 0.58. The price trend on GURU.Markets serves as an indicator of this process. Risks are mitigated through the parallel development of oncology treatments to attract new partners.

BMEA - Biomea Fusion Corp Market Price over the range 07/04/2022 - 11/14/2026

Biomea Fusion Inc - analytical breakdowns and key metrics (BMEA)

- stock quotes and analyst forecast:

Stock Price Biomea Fusion, Inc.|BMEA - Price Target Chart

- market capitalization information:

Market Value Biomea Fusion Inc|BMEA - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Value per Share Biomea Fusion|BMEA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio biomeafusion.com|BMEA - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and market ratios statistics:

BMEA - Net Income|Projected Future Earnings Biomea Fusion, Inc.|BMEA - P/E Multiple|Projected Price to Earnings Biomea Fusion|BMEA - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biomea Fusion Inc|BMEA - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Biomea Fusion|BMEA - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months biomeafusion.com|BMEA - Net earnings per one share growth for the current year|Earnings growth forecast for next year Biomea Fusion, Inc.

- sales and revenue data:

BMEA - Revenue and Sales Volume|Projected Sales Volume Biomea Fusion, Inc.|BMEA - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Biomea Fusion Inc

Fundamental valuation:Biomea Fusion, Inc.

Identifying fundamentally resilient assets requires analyzing market capitalization divided by the total shares outstanding, which allows for an assessment of the current investor consensus regarding business value. For Biomea Fusion, Inc. (BMEA), the price trend reflects market expectations for the success of its beta-cell regeneration R&D pipeline, turning every price level into an indicator of industry confidence in forthcoming clinical breakthroughs.

Analysis of competing companies